ATHA Athira Pharma, Inc. (Common Stock, NASDAQ) Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
13:48
Jan 02
Jan 02
Athira trades below cash with Phase 3 oncology catalyst.
The author argues Athira Pharma is deeply undervalued because its post-acquisition market cap (~$29M) is far below its ~$110M cash position while it now owns Phase 3 oncology drug Lasofoxifene. The investment mechanism is that positive Phase 2 PFS data for Lasofoxifene plus an upcoming mid-2027 Phase 3 ELAINE-3 readout should re-rate the stock, with added optionality from ATH-1105 ALS Phase 2 biomarker results in 2026. Author price targets are $12–15 by 2026, $35–45 by 2027 on Phase 3 success, and $75–100 by 2028–2030 on approval/M&A. The main stated risk is Phase 3 failure, which could send the stock back to ~$4.00 cash-shell value.
HIGH
About ATHA Investor Commentary
Across the available history and selected sources, Buzzberg tracks ATHA (Athira Pharma, Inc. (Common Stock, NASDAQ)) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/mister-pg.